Tumor vasculature is a key determinant for the efficiency of nanoparticle-mediated siRNA delivery

Gene Therapy

Volumn 19, Issue 7, 2012, Pages 775-780

  Li, L ^a   Wang, R ^a   Wilcox, D ^a   Zhao, X ^a   Song, J ^a   Lin, X ^a   Kohlbrenner, W M ^a   Fesik, S W ^a   Shen, Y ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

cancer; delivery; RNAi; siRNA

Indexed keywords

BETA GALACTOSIDASE; LIPOSOME; NANOPARTICLE; SMALL INTERFERING RNA; STABLE NUCLEIC ACID LIPID PARTICLE; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HEPG2; CONTROLLED STUDY; FEMALE; GENE DELIVERY SYSTEM; LIVER TUMOR; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VASCULARIZATION; TUMOR VOLUME; UPREGULATION;

ANIMALS; BETA-GALACTOSIDASE; CELL HYPOXIA; CELL LINE, TUMOR; FEMALE; GENE TRANSFER TECHNIQUES; GENETIC THERAPY; HUMANS; LIVER NEOPLASMS; MICE; MICE, SCID; NANOPARTICLES; RNA, SMALL INTERFERING; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84863721493     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2011.146     Document Type: Article

References (12)

1. de Fougerolles A, Vornlocher HP, Maraganore J, Lieberman J. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 2007; 6: 443-453. (Pubitemid 47064567)
2. Shen Y. Advances in the development of siRNA-based therapeutics for cancer. IDrugs 2008; 11: 572-578.
3. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol 2008; 26: 561-569. (Pubitemid 351668042)
4. Aleku M, Schulz P, Keil O, Santel A, Schaeper U, Dieckhoff B et al. Atu027, a liposomal small interfering RNA formulation targeting protein kinase N3, inhibits cancer progression. Cancer Res 2008; 68: 9788-9798.
5. Hu-Lieskovan S, Heidel JD, Bartlett DW, Davis ME, Triche TJ. Sequence-specific knockdown of EWS-FLI1 by targeted, nonviral delivery of small interfering RNA inhibits tumor growth in a murine model of metastatic Ewing's sarcoma. Cancer Res 2005; 65: 8984-8992. (Pubitemid 41377390)
6. Zimmermann TS, Lee AC, Akinc A, Bramlage B, Bumcrot D, Fedoruk MN et al. RNAimediated gene silencing in non-human primates. Nature 2006; 441: 111-114.
7. Rozema DB, Lewis DL, Wakefield DH, Wong SC, Klein JJ, Roesch PL et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes. Proc Natl Acad Sci USA 2007; 104: 12982-12987. (Pubitemid 351737577)
8. Judge AD, Robbins M, Tavakoli I, Levi J, Hu L, Fronda A et al. Confirming the RNAimediated mechanism of action of siRNA-based cancer therapeutics in mice. J Clin Invest 2009; 119: 661-673.
9. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK et al. Rational design of cationic lipids for siRNA delivery. Nat Biotechnol 2010; 28: 172-176.
10. Lin X, Li L, Wang R, Wilcox D, Zhao X, Song J et al. A robust in vivo positive-readout system for monitoring siRNA delivery to xenograft tumors. RNA 2011; 17: 603-612.
11. Morgan-Lappe SE, Tucker LA, Huang X, Zhang Q, Sarthy AV, Zakula D et al. Identification of Ras-related nuclear protein, targeting protein for xenopus kinesin-like protein 2, and stearoyl-CoA desaturase 1 as promising cancer targets from an RNAi-based screen. Cancer Res 2007; 67: 4390-4398. (Pubitemid 46815088)
12. Li L, Lin X, Staver M, Shoemaker A, Semizarov D, Fesik SW et al. Evaluating hypoxiainducible factor-1alpha as a cancer therapeutic target via inducible RNA interference in vivo. Cancer Res 2005; 65: 7249-7258. (Pubitemid 41161256)